267 related articles for article (PubMed ID: 26936994)
1. Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy.
Lapa C; Hänscheid H; Wild V; Pelzer T; Schirbel A; Werner RA; Droll S; Herrmann K; Buck AK; Lückerath K
Oncotarget; 2016 Apr; 7(15):20033-40. PubMed ID: 26936994
[TBL] [Abstract][Full Text] [Related]
2. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients.
Sollini M; Farioli D; Froio A; Chella A; Asti M; Boni R; Grassi E; Roncali M; Versari A; Erba PA
J Thorac Oncol; 2013 Aug; 8(8):1095-101. PubMed ID: 23857400
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
5. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
7. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
9. In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target.
Şen F; Sheikh GT; von Hinten J; Schindele A; Kircher M; Dierks A; Pfob CH; Serfling SE; Buck AK; Pelzer T; Higuchi T; Weich A; Bundschuh RA; Werner RA; Lapa C
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509258
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.
Park H; Subramaniam RM
PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.
Walker R; Deppen S; Smith G; Shi C; Lehman J; Clanton J; Moore B; Burns R; Grogan EL; Massion PP
PLoS One; 2017; 12(2):e0171301. PubMed ID: 28182730
[TBL] [Abstract][Full Text] [Related]
12. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
[TBL] [Abstract][Full Text] [Related]
13. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
Werner RA; Lapa C; Ilhan H; Higuchi T; Buck AK; Lehner S; Bartenstein P; Bengel F; Schatka I; Muegge DO; Papp L; Zsótér N; Große-Ophoff T; Essler M; Bundschuh RA
Oncotarget; 2017 Jan; 8(4):7039-7049. PubMed ID: 27705948
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
[TBL] [Abstract][Full Text] [Related]
15. Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT.
Weber M; Pettersson O; Seifert R; Schaarschmidt BM; Fendler WP; Rischpler C; Lahner H; Herrmann K; Sundin A
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):841-851. PubMed ID: 37947848
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pre-treatment
Aktan M; Koc M; Kanyilmaz G; Yavuz BB
Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer.
Serfling SE; Hartrampf PE; Zhi Y; Higuchi T; Kosmala A; Serfling J; Schirbel A; Hörning A; Buck AK; Weich A; Werner RA
Clin Nucl Med; 2023 Apr; 48(4):309-314. PubMed ID: 36754127
[TBL] [Abstract][Full Text] [Related]
18. 111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance.
Genestreti G; Bongiovanni A; Burgio MA; Burgio SL; Musto A; Rossi A; Monti M; Scarpi E; Ulivi P; Bravaccini S; Dubini A; Matteucci F; Gavelli G
Nucl Med Commun; 2015 Feb; 36(2):135-42. PubMed ID: 25321157
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin αvβ3.
Zheng Y; Wang H; Tan H; Cui X; Yao S; Zang J; Zhang L; Zhu Z
Clin Nucl Med; 2019 Sep; 44(9):687-694. PubMed ID: 31274560
[TBL] [Abstract][Full Text] [Related]
20. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog.
Edelman MJ; Clamon G; Kahn D; Magram M; Lister-James J; Line BR
J Thorac Oncol; 2009 Dec; 4(12):1550-4. PubMed ID: 19884860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
